Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice.
We investigated the treatment of remitting-relapsing experimental autoimmune encephalomyelitis (EAE) in mice with human bone marrow stromal cells (hBMSCs). hBMSCs were injected intravenously into EAE mice upon onset of paresis. Neurological functional tests were scored daily by grading clinical signs (score 0-5). Immunohistochemistry was performed to measure the transplanted hBMSCs, cell proliferation (bromodeoxyuridine, BrdU), oligodendrocyte progenitor cells (NG2), oligodendrocytes (RIP), and brain-derived neurotrophic factor (BDNF). The maximum clinical score and the average clinical scores were significantly decreased in the hBMSC-transplanted mice compared to the phosphate-buffered-saline-treated EAE controls, indicating a significant improvement in function. Demyelination significantly decreased, and BrdU(+) and BDNF(+) cells significantly increased in the hBMSC-treated mice compared to controls. Some BrdU(+) cells were colocalized with NG2(+) and RIP(+) immunostaining. hBMSCs also significantly reduced the numbers of vessels containing inflammatory cell infiltration. These data indicate that hBMSC treatment improved functional recovery after EAE in mice, possibly, via reducing inflammatory infiltrates and demyelination areas, stimulating oligodendrogenesis, and by elevating BDNF expression.
Zhang
Jing
J
Department of Neurology, Henry Ford Health Sciences Center, 2799 West Grand Boulevard, Detroit, MI 48202, USA.
Li
Yi
Y
Chen
Jieli
J
Cui
Yisheng
Y
Lu
Mei
M
Elias
Stanton B
SB
Mitchell
James B
JB
Hammill
Lora
L
Vanguri
Padmavathy
P
Chopp
Michael
M
D000818:Animals; D000941:Antigens / Q000378:metabolism; D001854:Bone Marrow Cells / Q000502:physiology*; D016026:Bone Marrow Transplantation / Q000379:methods*; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics / Q000378:metabolism; D001973:Bromodeoxyuridine / Q000378:metabolism; D002452:Cell Count / Q000379:methods; D049109:Cell Proliferation; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000139:chemically induced / Q000628:therapy*; D005260:Female; D015870:Gene Expression / Q000502:physiology; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D051379:Mice; D004676:Myelin Basic Protein / Q000378:metabolism; D018991:Myelin Proteolipid Protein; D009460:Neurologic Examination; D009842:Oligopeptides / Q000378:metabolism; D010446:Peptide Fragments; D011509:Proteoglycans / Q000378:metabolism; D012333:RNA, Messenger; D020127:Recovery of Function / Q000187:drug effects*; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D017154:Stromal Cells / Q000502:physiology; D013997:Time Factors; D000099216:Chondroitin Sulfate Proteoglycan 4
D000941:Antigens; D019208:Brain-Derived Neurotrophic Factor; D001973:Bromodeoxyuridine; D004676:Myelin Basic Protein; D018991:Myelin Proteolipid Protein; D009842:Oligopeptides; D010446:Peptide Fragments; D011509:Proteoglycans; D012333:RNA, Messenger; D000099216:Chondroitin Sulfate Proteoglycan 4; C111711:RNAIII inhibiting peptide; C435023:myelin proteolipid protein (139-151)